The brain microvasculature is a primary mediator of interferon-α neurotoxicity in human cerebral interferonopathies.
Aicardi-Goutières syndrome
blood-brain barrier
cerebral interferonopathy
endothelial
interferon-alpha
microangiopathy
neuroinflammation
neurotoxicity
small vessel disease
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
22
02
2022
revised:
10
01
2024
accepted:
17
05
2024
medline:
16
6
2024
pubmed:
16
6
2024
entrez:
15
6
2024
Statut:
aheadofprint
Résumé
Aicardi-Goutières syndrome (AGS) is an autoinflammatory disease characterized by aberrant interferon (IFN)-α production. The major cause of morbidity in AGS is brain disease, yet the primary source and target of neurotoxic IFN-α remain unclear. Here, we demonstrated that the brain was the primary source of neurotoxic IFN-α in AGS and confirmed the neurotoxicity of intracerebral IFN-α using astrocyte-driven Ifna1 misexpression in mice. Using single-cell RNA sequencing, we demonstrated that intracerebral IFN-α-activated receptor (IFNAR) signaling within cerebral endothelial cells caused a distinctive cerebral small vessel disease similar to that observed in individuals with AGS. Magnetic resonance imaging (MRI) and single-molecule ELISA revealed that central and not peripheral IFN-α was the primary determinant of microvascular disease in humans. Ablation of endothelial Ifnar1 in mice rescued microvascular disease, stopped the development of diffuse brain disease, and prolonged lifespan. These results identify the cerebral microvasculature as a primary mediator of IFN-α neurotoxicity in AGS, representing an accessible target for therapeutic intervention.
Identifiants
pubmed: 38878770
pii: S1074-7613(24)00271-1
doi: 10.1016/j.immuni.2024.05.017
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests I.L.C. and M.J.H. received funding from Ionis Pharmaceuticals for experiments in an unrelated study using the GIFN mice.